Stock futures pointed lower Monday and Treasury yields rose as Wall Street remained on edge over President Donald Trump’s ...

He is the head of HHS, and yet he continues to spout untested, unproven therapies and has only given a very lukewarm ...

The stock's rise snapped a three-day losing streak.

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies ...

The Dow Jones Industrial Average (DJIA) declined on Thursday despite many stocks on the index rising. Instead, a few major ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Pharmaceutical companies dominate the list of donors, which also includes HCA Healthcare, Centene, Molina Healthcare and the ...